Virtual Library

Start Your Search

R.P. Perez



Author of

  • +

    P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P2.01-069 - Design and Stratification for Phase III Trials in First-Line Non-Small Cell Lung Cancer (ID 80)

      09:30 - 09:30  |  Author(s): R.P. Perez

      • Abstract
      • Slides

      Background:
      Metastatic non-small cell lung cancer (NSCLC) remains an incurable disease. Sacher et al reviewed phase III studies in first-line advanced/metastatic NSCLC conducted from 1981 to 2010. Although trends in study outcomes were assessed, design and stratification factors have never been analyzed.

      Methods:
      The recently published list of phase III trials by Sacher et al (JCO 2014;32:1407-11) was reviewed thoroughly. Eligible trials for this study must have been published in the English literature between 1981 and 2010. Trials that included a substantial number of previously treated NSCLC patients were excluded. Maintenance studies after first-line chemotherapy were also excluded. Characteristics in each decade were determined for sample size, number of trials, region, rate of meeting accrual goal, primary endpoint, type of phase III, interim analysis, allocation method, and stratification factors (SFs). Any p-value of less than 0.05 was considered significant for statistical analysis.

      Results:
      A total of 162 studies were considered to meet the criteria. The number of studies and median sample size increased from 29 and 133 in 1980s to 46 and 181 in 1990s to 87 and 407 in 2000s, respectively. Primary endpoint was reported more frequently in recent decades; 24% of studies in 1980s, 83% in 1990s, 99% in 2000s. Non-overall survival endpoints were frequently chosen in European and Asian studies. Interim analysis was planned for 3% in 1980s, 20% in 1990s, 33% in 2000s. Allocation method was rarely reported throughout the three decades (0% in 1980s, 22% in 1990s, 28% in 2000s). The median number of SFs increased significantly from one in 1980s to three in 2000s (see Table). Performance status (PS), stage, and institution have been most frequently selected, and at least one of the three factors was used in most of the studies (84%) in 2000s. There are many other SFs that were used infrequently. More details will be presented. Table: SFs in first-line phase III NSCLC trials. All others; stratification factors other than PS, stage, and institution. The median number of SFs increased significantly (one way ANOVA, p=0.003).

      1981-1990 1991-2000 2001-2010 Total
      No. of studies 29 46 87 162
      Median no. of SFs 1 2 3 2
      PS 14(48%) 21(46) 48(55) 83(51)
      Stage 2(7) 22(48) 63(72) 86(53)
      Institution 2(7) 17(37) 37(43) 56(35)
      PS or Stage 15(52) 29(63) 6(7) 113(70)
      PS, Stage, or Institution 16(55) 32(70) 73(84) 121(75)
      Not reported or None 12(41) 13(28) 13(15) 38(23)
      All others 1(3) 1(2) 1(1) 3(2)


      Conclusion:
      This study reports extensive details in design of phase III trials for first-line NSCLC that have been published over three decades. We found increases in sample size and reporting primary endpoint, whereas allocation method remains underreported. Although PS, stage, and institution are the most frequently selected, choice of SFs remains inconsistent across studies. Our report provides researchers with valuable information for future studies.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.